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Abstract
Enhancing the affinity of therapeutic T cell receptors (TCR) without altering their specificity is a significant challenge for
adoptive immunotherapy. Current efforts have primarily relied on empirical approaches. Here, we used structural analyses
to identify a glycine-serine variation in the TCR that modulates antigen sensitivity. A G at position 107 within the CDR3b
stalk is encoded within a single mouse and human TCR, TRBV13-2 and TRBV12-5 respectively. Most TCR bear a S107. The S
hydroxymethyl side chain intercalates into the core of the CDR3b loop, stabilizing it. G107 TRBV possess a gap in their
CDR3b where this S hydroxymethyl moiety would fit. We predicted based on modeling and molecular dynamics simulations
that a G107S substitution would increase CDR3b stability and thereby augment receptor sensitivity. Experimentally, a G107S
replacement led to an ,10–1000 fold enhanced antigen sensitivity in 3 of 4 TRBV13-2+ TCR tested. Analysis of fine
specificity indicated a preserved binding orientation. These results support the feasibility of developing high affinity antigen
specific TCR for therapeutic purposes through the identification and manipulation of critical framework residues. They
further indicate that amino acid variations within TRBV not directly involved in ligand contact can program TCR sensitivity,
and suggest a role for CDR3 stability in this programming.
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Introduction
T cells endowed with new specificities by T cell receptor
(TCR) transduction have shown promise in cancer and other
diseases [1–3]. Inadequate affinity may limit the activity of
introduced TCR, and engineering enhanced responsiveness to
peptide MHC (pMHC) ligand is an important challenge [4].
Affinity-enhancement has generally involved empirical ap-
proaches, such as in vitro selection after random mutagenesis [5–
10]. Significantly, TCR binding to pMHC primarily results from
contact associations with MHC rather than peptide antigen
[11,12]. Random mutations that increase TCR affinity will
therefore often non-selectively increase affinity for MHC. Indeed,
T cells modified with TCR mutated and selected for high affinity
have been found to lose Ag specificity, responding to APCs alone
[5,8,13]. It would be anticipated that mutant TCR with smaller
affinity increases will likewise possess some increased reactivity to
MHC. This may convert subthreshold engagements with self or
other Ags into productive responses. Rational design, by using
known TCR structures to direct mutations to residues less likely to
alter Ag selectivity, may be a useful alternative to empirical
approaches to modulate TCR affinity.
We and others observed a disproportionate representation of
TRBV13-2+ TCR in myelin oligodendrocyte glycoprotein
(MOG)-induced experimental allergic encephalomyelitis (EAE).
Preferential TRBV13-2 use has also been seen in several other
autoimmune diseases in mice and responses to some antigens,
and TRBV13-2 is present on ,50% of the NK-T cell repertoire
[14–24]. Biased TRBV use need not indicate a clonal or
oligoclonal response, but may be associated with heterogeneous
TRAV and CDR3b sequences, a feature we identified after
sequencing TCR from MOG-specific T cell clones [25,26]. Bias
may arise because specific V regions’ CDRs have a predilection
for specific Ags or binding orientations on MHC molecules
[12,27,28].
To better understand structural differences that may underlie
the preferential use of TRBV13-2 TCR, we aligned its sequence
with that of other TRBV. We observed that most CDR3b
incorporate a conserved N-terminal CASS motif in both mice
(18/23 TRBV sequences) and humans (45/54) (Supp. Table S1).
TRBV13-2 in mice and TRBV12-5 in humans were exceptions.
These, unique to their species, bear a CASG motif. The S/G
residues are buried within the CDR3b structure, not surface
exposed. Structural studies demonstrated that a G107 leaves a
gap in the CDR3b core, which we hypothesized would
destabilize this critical antigen recognition domain. We predict-
ed that a G107S substitution in TRBV13-2 TCR, would
stabilize the CDR3b loop in configurations that retain antigen
specificity, and could thereby increase TCR affinity for cognate
ligand.
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Methods
Ethics Statement
Studies were approved by and followed guidelines of the St.
Jude Children’s Research Hospital Animal Care and Use
Committee (protocol 338).
Mice
C57BL/6J (B6), B10.BR, and NOD/ShiLtJ mice were obtained
from The Jackson Laboratory (Bar Harbor, ME), and B6.129-
H2dlAb1-Ea/J (class II2/2) mice from Dr. P. Doherty (St. Jude
Children’s Research Hospital, Memphis, TN).
TCR structures
TCR amino acid assignment is per International Immunoge-
netics Information System (IMGT) conventions (imgt.cines.fr).
TCR structures were aligned, H-bonds calculated, and interatom-
ic distances measured using Swiss PDB viewer v3.7. Images were
produced and surfaces calculated using the PyMol molecular
graphics system v1.1r1.
Molecular Dynamics
The ab TCR was extracted from the crystal structure of mouse
172.10 TCR complexed with pMHC (PDB ID: 1U3H). The b
chain G107 was mutated to S with Swiss-Pdb viewer v3.7. Both
the wt and the G107S structure complex were used as the starting
points for molecular dynamics using Amber v10 software. The GB
solvent model was used to mimic the solvent effect implicitly.
Model and parameters were as described [29]. Amber FF03 force
field [30] was used in all calculations, which consisted of 3 steps: a.
10000 cycles of energy minimization; b. 50 picoseconds of
equilibration at constant volume by coupling the system to the
Berendsen Heat bath with a constant temperature of 300K
(canonical ensemble); c. 4.5 ns of molecular dynamics. The
simulation setups were exactly the same for the WT and mutant
complex. The RMSD values and potential energy values were
obtained with Amber analysis tools. The covariance matrix
method [31] was used to calculate entropies of the b chain
CDR3 loop [104CAS(G/S)DAGGGYEQYFGP119]; the set of b
chain CDR3 loop backbone N, C, Ca atoms were included in the
entropy calculations.
Peptides, Antibodies, and Flow Cytometry
MOG35–55 (MEVGWYRSPFSRVVHLYRNGK), alanine substi-
tutions of this, GAD206–220, (TYEIAPVFVLLEYVT), and HEL48–62
(DGSTDYGILQINSRW) were synthesized and HPLC purified by
the St. Jude Hartwell Center. Monoclonal antibodies (mAbs) specific
for CD4 (clone H129.19) and TCR Vb8.1, 8.2 (clone MR5-2) were
from BD Biosciences. Flow cytometry was performed on a
FACSCalibur (BD Biosciences), and flow cytometric sorting on a
MoFlo high-speed cell sorter (DakoCytomation).
TCR constructs and mutagenesis
The 1MOG9, 1 MOG244.2 [25], 3A9 [32], and PA19.5E11
[33], TCR a and b chains were isolated by PCR and cloned into
the MSCV-I-GFP murine stem cell virus-based retroviral vector as
described [25]. Site-directed mutagenesis was performed using the
Quickchange II Site Directed Mutagenesis kit (Stratagene) and
confirmed by DNA sequencing.
Retroviral transduction
Retrovirus was produced as described [5] and used to infect
surface TCR-deficient 4G4 or 4G4.CD4 T hybridoma cells.
Transduced cells were flow cytometrically sorted on day 4 or 5 for
TCR expression.
Cytokine analysis
Transduced T cells were purified by flow cytometric sorting and
expanded. Cells were cultured at 56104 per well with 36105
3000-rad irradiated APCs and the indicated stimulus. Culture
supernatant was collected at 24 h and analyzed for IL-2 by
sandwich ELISA (BD Pharmingen) or Bio-Plex (Bio-Rad) assay.
Samples were analyzed in triplicate.
Results
Comparative analysis of CDR3b in TRBV13-2 and other
TCR
The N-terminal sequence of TRBV13-2+ CDR3b in mice and
TRBV12-5+ CDR3b in humans is 104CASG. This contrasts with
the 104CASS sequence in the majority of TRBV loci (78% in mice,
83% in humans; Supp. Table S1 and Supp. Fig. S1). Coordinates
for three TRBV bearing the CASG motif and seven with the
CASS motif were aligned to define the molecular consequences of
this G/S variation. Overlay plots of the TCR, highlighting just the
CDR3b showed tight juxtaposition of the peptidyl backbones of
the CDR3 stalks, which includes the G/S variant residue (Fig. 1a).
Figure 1. Impact of a G versus S residue at TCRb position 107. (A)
Three TRBV13-2 (silver) and 7 non-TRBV13-2 (blue) TCRab structures (listed
in the text) were aligned. Their CDR3b peptidyl backbones are displayed in
two orientations, indicating highly conserved stem structures. G107
residues are in pink and S107 in red. The structural impact of a G107 versus
S107 is exemplified in the mouse TRBV13-2+ 172.10 TCR (B) and TRBV13-3+
AHIII 12.2 TCR (C). The arrow indicates the location of the S107 side chain in
AHIII 12.2 that is absent in the 172.10 TCR.
doi:10.1371/journal.pone.0018027.g001
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This was true regardless of TCR source, human or mouse, or the
alternative presence of G or S at position 107. In contrast to the
stalks, backbones of the surface exposed CDR3b loops showed
greater variability.
Two consistent differences were attributable to the G/S
variation. First, a G107 left a gap within the center of the CDR3b
loop (Fig. 1b, TRBV13-2+ 172.10 TCR; see Supp. Fig. S2a for
other structures). When an S was present, its hydroxymethyl side
chain was oriented to intercalate into this space, thereby
generating van der Waals interactions with other residues
(Fig. 1c, TRBV13-3+ AHIII 12.2 TCR; Supp. Fig. S2b). Second,
for 6/7 of the CASS structures, the S107 hydroxyl moiety was
oriented outside of the plane of the CDR3 loop (Fig. 2a). This
facilitated hydrogen bonding with backbone CDR3b residues
upstream from the S residue and, when present, a Y40 side chain
occupying a TRBV b-sheet strand juxtaposed to the CDR3
(Fig. 2b; AHIII 12.2 TCR). For 1/7 CASS TCR, KK50.4, the
S107 hydroxymethyl was oriented in the plane of the CDR3,
forming H bonds with both immediately upstream and counter-
current residues of the loop (Fig. 2c). Therefore S107 bonds both
through van der Waals interactions and H-bonding with adjacent
residues. This would be anticipated to stabilize CASS but not
CASG CDR3b structures.
Absence of structural accommodation to G107
It was possible that CASG TCR had an altered configuration
compared with CASS TCR, compensating for the space vacated
by the S107 side chain. This was however not apparent. Distance
between the TRBV G107 or S107 backbone a carbon and the
most proximate TRBJ backbone carbonyl carbon on the opposing
CDR3 strand were not significantly different regardless of whether
a G or S was present at position 107 (Fig. 2d distance a and
Table 1). This was likewise true for distances between the 107
backbone carbon and that of the Y40 side chain oxygen (Fig. 2d,
distance b) or the backbone a carbon of the opposed beta sheet
residue 2 amino acids upstream of this Y (Fig. 2d, distance c). The
single exception among the tight clustering of interatomic
distances among the TCR was the CASS-containing, myelin
basic protein-specific, 3A6 TCR, which showed increased
interatomic distances (Table 1). This, together with the atypical
structural gap above the S107 position of the 3A6 CDR3b (Supp.
Fig. S2b), argues for a distinct orientation of this autoreactive
CDR3b loop. Overall, however, the data indicates that crystal-
lographically-determined TCR spatial configuration is not signif-
icantly impacted by a G versus an S residue at 107.
The failure of G107 TCR to accommodate for the absence of a
hydroxymethyl side chain suggested that a G107S substitution
Figure 2. S107 hydroxymethyl positioning within the CDR3b loop. (A) Positions of the S107 hydroxymethyl side chains (yellow) for 7
overlayed TCR structures. (B) The S107 hydroxyl in the AHIII12.2 TCR is oriented outside of the plane of the CDR3b loop, permitting H-bonding with
the backbone carboxyl O of D108 and the side chain hydroxyl of Y40. H-bonds are indicated by dashed lines, and distances by numbers in A˚. (C) The
S107 hydroxyl in the KK50.4 TCR is within the plane of the CDR3b loop, permitting H-bonding with the backbone carboxyl O of R110, the D109 side
chain, and carboxyl oxygen of T112. (D) Distances were measured between the a carbon of the S or G at 107 and the backbone carbonyl carbon of
the most proximate amino acid in the countercurrent strand of the CDR3b (distance a), the Y40 O if present (distance b), and the a carbon of TRBV
residue 42 (distance c). The diagram, derived from the KK50.4 TCR, shows peptidyl backbone only with the exception of the Y40 side chain.
doi:10.1371/journal.pone.0018027.g002
Modulation of TCR Sensitivity
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18027
Table 1. Interatomic distances in G107 or S107 TCR.
TCR TRBV13-2 PDB ID CDR3b Distance a Distance b Distance c
D10 Y 1D9K CASGGQGRAEQFF 4.81 5.73 5.40
172.10 Y 1U3H CASGDAGGGYEQYF 4.98 5.28 4.90
2C Y 2OI9 CASGGGGTLYF 5.12 5.25 4.85
Mean 6 S.D. 4.9760.16 5.4260.27 5.0560.30
HA1.7 N 1FYT CASSSTGLPYGYTF 5.06 NA 4.82
AHIII 12.2 N 1LP9 CASSDWVSYEQYF 5.17 4.95 4.88
N15 N 1NFD CASSLRWGDEQYF 4.55 NA 5.26
JM22 N 1OGA CASSRSSYEQYF 4.59 6.04 4.96
1G4 N 2BNQ CASSYVGNTGELFF 4.82 NA 4.98
KK50.4 N 2ESV CASSQDRDTQYF 4.84 5.67 4.93
3A6 N 1ZGL CASSLADRVNTEAFF 6.12 NA 5.60
Mean 6 S.D. 5.0260.53 5.5560.55 5.0660.28
TCR with a G107 (TRBV13-2+) or S107 (TRBV13-22) TCRb were analyzed. Distances measured are indicated in Fig. 2d and the text, and are measured in A˚. PDB ID and
CDR3b sequence of structures studied are listed.
doi:10.1371/journal.pone.0018027.t001
Figure 3. Modeling of a G107S mutation in the 172.10 TCR. (A) Arrow and yellow colored carbon atoms indicate the position of G107 within
172.10. A gap is noticeable within the center of the CDR3b. (B) A G107S substitution, modeled without altering the atomic positions of other amino
acids, demonstrates the potential for the S hydroxymethyl to fill the gap. (C) Addition of the Y40 side chain to the structure in (B) using coordinates
from the original 172.10 structure further shows accommodation of the G107S substitution. (D) Removal of side chains of select amino acids and
rotation of the structure relative to (C) demonstrates the juxtaposition and potential for H bonding between the inserted S107 hydroxyl, the D108
carboxyl O, and the Y40 side chain hydroxyphenyl in a manner corresponding to that observed in the AHIII 12.2 and other TRBV13-22 TCR crystal
structures (see Fig. 2b).
doi:10.1371/journal.pone.0018027.g003
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should fit within the CDR3b in TRBV13-2+ TCR. Modeling of
G107S mutations indeed showed that the solved 172.10, D10, and
2C crystal structures could contain the additional hydroxymethyl
group in orientations equivalent to that seen in the CASS TCR
without modifying any other atomic positions (Fig. 3a–d and not
shown). Therefore, a gap is left in G107 TCR that is able to hold
an S107 side chain. This gap would be anticipated to destabilize
the CDR3b. A G107S substitution would be expected to stabilize
the CDR3b structure by H-bonding and van der Waals
interactions with neighboring residues, and if able to maintain a
conformation favorable for pMHC interactions should increase
TCR reactivity.
Figure 4. Enhanced antigen sensitivity mediated by a G107S
substitution. (A) The 1MOG9 wt or G107S TCR were transduced into
4G4 or 4G4.CD4 TCRab-deficient hybridoma cells. The cell lines were
flow cytometrically sorted for equivalent TCR expression and stimulated
with MOG35–55 peptide or aCD3 and irradiated C57BL/6 or class II
2/2
splenic APCs as indicated. IL-2 production was measured at 24 h. Similar
studies were performed with 4G4.CD4 cells transduced with wt or
G107S substituted 1MOG244.2 (B), PA-19 (C), and 3A9 TCR (D).
doi:10.1371/journal.pone.0018027.g004
Figure 5. Selectivity of the G107S mutation. 1MOG9 TCR was
mutated to insert all other amino acids at position 107. TCR-transduced
4G4.CD4 cells, sorted for equivalent TCR expression, were stimulated
with titrations of MOG35–55. (A) TCR with amino acid substitutions
leading to a diminished (A) or enhanced or similar (B) response
compared with the wt 1MOG9 are shown.
doi:10.1371/journal.pone.0018027.g005
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Enhanced responsiveness of G107S TCR
To test the impact of G107S substitutions on TRBV13-2+
TCR, we generated these in 2 MOG specific TCR we previously
cloned, 1MOG9 and 1MOG244.2 [25]. These TCR bear CDR3
identical in length to the crystallized TRBV13-2+ 172.10 TCR
described above. Sequence was also similar; only a single amino
acid differed between the CDR3b of 172.10 and 1MOG244.2
and 5 amino acids differed with 1MOG9 (172.10: CASGDAGG-
GYEQYF; 1MOG9: CASGDWGGEDTLYF; 1MOG244.2:
CASGDAGTGYEQYF). Considering the conserved structures
of TCR V regions in general and the identical length and nearly
identical sequences of these TCRb, their frameworks should be
similar.
We transduced retrovirus incorporating wt or G107S 1MOG9
or 1MOG244.2 TCR into TCRab-deficient 4G4.CD4 T cell
hybridomas. Cells were sorted for similar TCR expression levels
and stimulated with titrations of MOG35–55 peptide. Because the
wt and G107S TCR-transduced 4G4.CD4 cells were essentially
identical except for the single amino acid difference in the CDR3b
at position 107, response sensitivity to MOG35–55 should primarily
reflect TCR binding affinity.
The 1MOG9 G107S TCR dramatically increased MOG35–55
sensitivity, ,1000 fold, and substantially increased maximal
response (Fig. 4a). This did not result from acquisition of
antigen-independent responsiveness, as neither wt nor G107S
TCR-transduced cells responded to APC in the absence of
antigen. Further, response remained class II MHC restricted as
neither cell type responded to antigen in the presence of class II
MHC2/2 APC. Therefore the addition of a single hydroxymethyl
moiety within the center of the CDR3b loop can dramatically alter
TCR sensitivity.
The presence of CD4 co-receptor boosts TCR signaling by
recruiting the downstream kinase lck and, to a lesser extent, by its
adherence to class II MHC [34]. To test whether increased
antigen sensitivity of G107S TCR led to co-receptor indepen-
dence, we also transduced wild type or G107S 1MOG9 receptor
into 4G4 T cells lacking CD4 or CD8 co-receptor. Whereas no
response was detected among the 1MOG9 T cells at any
concentration of Ag, response was seen with the 1MOG9
G107S mutant, though this was diminished ,3log10 compared
with transductants expressing CD4 (Fig. 4a).
Analysis of the 1MOG244.2 TCR also demonstrated increased
sensitivity with the G107S substitution. This, however, was more
moderate, with a 5–10 fold increase (Fig. 4b). To determine if
increased antigen responsiveness could also be seen with TCR
specific for other antigens, we generated similar substitutions in two
additional TRBV13-2+ TCR, the glutamic acid decarboxylase
(GAD)206–220/IA
g7-specific PA19 and hen egg lysozyme (HEL)46–61
/IAk-specific 3A9 receptors. The presence of an S107 increased
antigen sensitivity ,100 fold in the PA19 TCR whereas it
abolished recognition in the 3A9 TCR (Fig. 4c, d). Therefore,
consistent with structural predictions, the addition of a hydro-
xymethyl moiety to G107 can increase antigen sensitivity among
some TCR. Impressively, 3 of 4 analyzed TCR displayed an
increase in antigen sensitivity of ,10–1000 fold. The loss of
reactivity in 1/4 of the TCR is not surprising as conformational
limitations imposed by the S107 may conceivably hinder
recognition.
Specificity of S at position 107
Considering the relatively conserved use of a CASS motif in
CDR3b, we anticipated that the increased antigen sensitivity
endowed by the S substitution would be specific to this residue. To
test this, we substituted the remaining 18 amino acids at the G107
position in the 1MOG9 TCR. Transduced 4G4.CD4 cells were
again sorted for similar TCR expression levels (Supp. Fig. S3). Of
the substituted TCR, 15 diminished antigen sensitivity when
compared with wt TCR, or abolished recognition (Fig. 5a). A
G107C substitution showed sensitivity similar to that of the wild
type receptor (Fig. 5b). An A and to a lesser extent F substitution
increased antigen sensitivity,100 fold, substantial though to a less
than the ,1000 fold increase with the S substitution. Structural
modeling of the G107A suggested that it would situate similarly to
the S, though it lacks the S hydroxyl. In contrast, the enhanced
sensitivity of the bulky hydrophobic F substitution undoubtedly
occurs through structurally distinct interactions. Therefore, few
amino acid changes at position 107 can enhance TCR response,
and the conserved S present in most CDR3b is specifically well
suited for this location.
Fine specificity of TCR recognition
Our modeling showed that a G107S substitution can fit within
the center of a CDR3b without substantially altering its overall
structure, suggesting that a G107S mutation should not promi-
nently impact fine specificity of pMHC recognition. To test this,
we assessed IL-2 production against a panel of 15 ala-substituted
MOG35–55 peptides by 1MOG9 or 1MOG244.2 and the
equivalent G107S-modified T cells. Data was normalized against
the response to unmodified peptide. The overall response pattern
of the TCR was similar. Ala substitutions in S42, P43, F44, and
R46 strongly diminished responses by both the 1MOG9 and
1MOG244.2 TCR (Fig. 6a, b). No difference in the wt and G107S
modified TCR using either high or low concentrations of Ag was
observed for these critical residues. Some differences were
observed with other ala substitutions. Specifically, for the
1MOG9 TCR and its G107S mutant, responses differed to
G38A and W39A substitutions after stimulating with 100 mg/ml
peptide, and W39A, Y40A, and V47A with 10 mg/ml peptide.
However, of these only W39A remained significantly different in
repeat experiments, and only in one of two additional analyses at
10 mg/ml (data not shown). In contrast to the 1MOG9 TCR, no
significant differences were observed when comparing the
1MOG244.2 wt and G107S responses to any of the substituted
peptides. Therefore the G107S mutation enhances sensitivity in
the MOG-specific TCR. However, consistent differences in
response to ala-substituted peptides were not reliably obtained
and response to the MOG35–55 residues critically required for
TCR response did not differ. This indicates that core recognition
is preserved when comparing the wt and G107S TCR.
Discussion
Greater than 20 and 50 TRBV are available in mice and
humans respectively, yet specific immune responses may rely on
just one or a few of these [27]. G107 is unique to TRBV13-2 in
mice and TRBV12-5 in humans. In each species, other TRBV
dominantly express a S at this location. As the hydroxymethyl side
Figure 6. Fine specificity of wt and G107S TCR. To determine if the G107S substitution influenced fine specificity, 1MOG9 (A) or 1MOG244.2 (B)
transduced 4G4.CD4 cells or their corresponding G107S mutants were stimulated with 10 or 100 mg/ml of the indicated A-substituted MOG35–55
peptides. IL-2 production, normalized to the response to wt MOG35–55, is plotted. Plots are representative of 3 independent studies performed with
10 mg/ml and 2 with 100 mg/ml peptide Ag. *, p,0.05 by ANOVA.
doi:10.1371/journal.pone.0018027.g006
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chain of the more common S is positioned to intercalate into the
core of the CDR3b loop, we reasoned that alternative amino acids
at that position should distort the CDR3b’s conformation and
thereby influence pMHC recognition. Surprisingly, our evaluation
of previously characterized TCR structures indicated that the
absence of a S107 side chain in TRBV13-2+ TCR did not lead to
substantive structural alterations. TRBV13-2+ and other TCR
were similar, but a gap was left in TRBV13-2+ receptors where a S
hydroxymethyl would otherwise fit. Modeling indicated that
TRBV13-2+ TCR could accommodate a GRS substitution
without displacement of any other residue, indicating that the
bonding provided by the S107 hydroxymethyl is not essential to
preserve CDR3b structure. We predicted that the gap present in
TRBV13-2 CDR3b will be energetically unfavorable, and that a
G107S replacement will increase the stability and hence affinity of
TRBV13-2+ TCR. This was born out in our experimental
findings, as 3 of 4 TRBV13-2+ TCR showed increased
responsiveness after G107S modification.
Biophysical analyses of G107S TCR will be needed to fully
evaluate the mechanism of their enhanced reactivity. We can
however speculate on the structural impact of the substitution. The
free energy of TCR binding to pMHC will be proportional to the
change in enthalpy, or chemical heat, associated with their
interaction, and inversely proportional to the change in entropy,
or randomness, in the molecules. CDR flexibility, which will be
related to entropy, is a fundamental element of current models of
TCR–pMHC engagement, allowing TCR to optimally conform to
the surface of its ligand. Indeed, molecular accommodation was
apparent in solved structures of individual TCR bound to different
pMHC complexes or when comparing free and pMHC-bound
TCR [11]. An inverse relationship has also been observed between
TCR avidity and degeneracy, indicating that as TCR gain
flexibility and an increasing ability to bind different ligands they
also lose binding affinity [35,36]. A single report has specifically
examined the motion within a single chain TCR using NMR
spectroscopy [37]. Interestingly, this identified enhanced CDR3
motility in the TRBV13-2+ D10 TCR.
Studies with antibodies have more clearly demonstrated the role
of entropy in modulating binding affinity. In some cases, affinity is
heavily governed by entropic features. Specific residue changes,
such as occurs with affinity maturation, may enhance affinity by
modulating receptor entropy [38–40]. Therefore, molecular
alterations that influence CDR entropy may also affect affinity.
The G107S substitution in TCR assessed here, by stabilizing the
CDR3b loop through H-bonding and van der Waals interactions
would be expected to diminish receptor entropy. This may
enhance affinity if it is not superseded by opposing enthalpic
changes.
As an initial assessment of the impact of a G107S substitution on
TCR entropy, we analyzed the molecular dynamics (MD) of
TRBV13-2 CDR3b in silico (Fig. 7). The crystallographically
defined 172.10 TCRab structure without pMHC ligand and with
or without a G107S substitution underwent initial energy
minimization followed by 4.5 ns MD in an implicit solvent model
using Amber software. Structures stabilized after ,2.5 ns. The
G107S mutant displayed overall preserved structural integrity, and
indeed both the entire TCR structure and the CDR3b peptidyl
backbone had a lower root backbone mean square deviation
(RMSD) from the initial minimized structure than the wt TCR
(Fig. 7a). Both the wt and G107S TCR showed similar overall
stabilities (Fig. 7b). More interestingly, the G107S CDR3b showed
diminished motility compared with the wt, corresponding to a
decrease in the mutant’s entropy (Fig. 7c). Although the change in
entropy was a small percent of total entropy, we can estimate that
this magnitude of change may potentially lead to a .2log10
difference in binding affinity (not shown).
These MD results are therefore consistent with the hypothesis
that a G107S substitution promotes TCR affinity by diminishing
entropy. Certainly, though, entropic modulation will not be
independent of enthalpic changes, and a full assessment of this will
require direct binding measurements of the TCR in association
with their ligands. Indeed, restrictions in CDR3b flexibility may
exclude conformations enthalpically favorable for pMHC inter-
action, and could explain the loss of reactivity in the 3A9 TCR
with a G107S mutation.
It is interesting to further speculate that G107 is also important in
the increased use of TRBV13-2 in NK-T cells and specific
autoimmune models, for instance by enhancing flexibility and
degeneracy of these TCR. Similar concepts have been raised and
debated previously [41,42]. Our findings may indicate relevance of
the G107 in the preferential use of this TCR. However, it would
seem unlikely that the variation at position 107 is an exclusive control
point in establishing response thresholds among different TCR.
Rather, other amino acid variations in proximity to the CDR3
would be expected to similarly influence TCR responsiveness.
Importantly, the ability to modulate TCR affinity is of
considerable therapeutic concern. Genetically modified T cells
transduced with TCR specific for tumor antigens have shown
efficacy in clinical trials, which are being expanded to include
mutated TCR [5,6,13,43]. TCR modified T cells may have use in
cancer, autoimmunity, and infection. We and others have shown
that such mutated TCR may also develop altered antigen
specificity, particularly the acquisition of self-reactivity. Substitut-
ing a S in G107-bearing TRBV, which we hypothesize acts by
stabilizing the CDR3b rather than through altered binding to
MHC, may potentially boost overall sensitivity without substan-
tially altering specificity. Indeed, we did not observe peptide-
independent APC reactivity, or altered fine specificity with this
modification. In summary, our results provide evidence for a
genetic variation in a single amino acid in a non-pMHC contact
residue of a TCR V gene controlling TCR sensitivity for antigen,
and support a new approach to generate high affinity TCR for
therapeutic purposes through modification of G107+ TCR.
Supporting Information
Figure S1 Location of G/S107 variation in CDR3.
Structural model of the 172.10 TCR (PDB ID: 1U3H)
demonstrating the CDR3b (yellow) associating with MHC-bound
peptide (red). The TCRb chain is in green and a chain in purple.
The position of the G/S variation is in pink.
(EPS)
Figure S2 CDR3b structures. Aligned structures of character-
ized CDR3b loops from TCR with a G107 are shown in (A) and
with an S107 in (B). The G or S107 residues are colored yellow. The
Figure 7. Molecular Dynamics analysis of a G107S mutation. WT or G107S mutant 172.10 TCR underwent 4.5 ns of MD. (A) RMSD from initial
structure of the TCRab or the CDR3b is plotted versus time of MD. (B) Potential energies, an indicator of overall structural stability, of TCRab structures
during the course of MD is plotted. (C) Entropic analysis of the CDR3b backbone is shown. Inset demonstrates the difference in entropy between wt
and mutant CDR3b.
doi:10.1371/journal.pone.0018027.g007
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position of the S107 hydroxymethyl side chain, or the equivalent
position for TCR bearing a G107, is indicated by the arrow.
(EPS)
Figure S3 TCR expression in TCR transduced 4G4.CD4
T cells. 4G4.CD4 T cells were transduced with the 1MOG9 or
indicated mutant TCR, expanded, and flow cytometrically sorted
for TCR expression. TCR expression levels for untransduced
4G4.CD4 cells or for the indicated transduced lines is shown.
(EPS)
Table S1 Aligned sequences of the V region of TCR
CDR3b. Sequences of the C-termini of human and mouse TRBV
identified using the Immunogentics Information System (imgt.ci-
nes.fr) are indicated, and begin at the conserved C at position 104.
A S at position 107 is indicated by a red color, and a G by a green
color. The majority of mouse and human TRBV have a CASS
motif at this site.
(DOC)
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